Video Experimental Relacionado
Updated: Jul 16, 2026
08:03
Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
Published on: June 25, 2017
Aumento de la actividad de la endotelina endógena en pacientes con diabetes mellitus tipo II
Carmine Cardillo1, Umberto Campia, Melissa B Bryant
1Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md, USA.
Circulation
|October 3, 2002
Resumen
La actividad de la endotelina-1 (ET-1) en los receptores ET(A) aumenta en los vasos sanguíneos de los pacientes diabéticos, mientras que la sensibilidad a ET-1 disminuye. Esto puede contribuir a las complicaciones vasculares en la diabetes.
Área de la Ciencia:
- Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular
- Endocrinología Endocrinología.
- Biología Vascular Biología Vascular
Sus antecedentes:
- La disfunción endotelial está relacionada con la aterosclerosis en la diabetes.
- Endothelin-1 (ET-1) puede promover la mitogénesis de las células del músculo liso y la adhesión de leucocitos.
- Investigar la actividad endógena de ET-1 en la diabetes tipo II es crucial.
Objetivo del estudio:
- Para evaluar la actividad endógena de ET-1 en pacientes con diabetes tipo II utilizando antagonistas de los receptores ET-1.
- Para comparar las respuestas del flujo sanguíneo del antebrazo (FBF) al bloqueo del receptor ET-1 y al ET-1 exógeno entre pacientes diabéticos y controles.
Principales métodos:
- Las respuestas al flujo sanguíneo en el antebrazo (FBF) se midieron utilizando una pletismografía con manómetro de tensión.
- Se realizó un bloqueo selectivo del receptor ET(A) (BQ-123) y una infusión de ET-1 por vía intraarterial.
- Se hicieron comparaciones entre 15 pacientes diabéticos y 12 controles sanos.
Principales resultados:
- BQ-123 indujo una vasodilatación significativa en pacientes diabéticos, a diferencia de los controles.
- La ET-1 exógena causó vasoconstricción embotada en pacientes diabéticos en comparación con los controles.
- Las respuestas al vasoconstrictor de la norepinefrina fueron similares en ambos grupos.
Conclusiones:
- La actividad endógena de ET-1 en los receptores ET(A) se mejora en los vasos de resistencia diabética.
- Los pacientes diabéticos presentan una sensibilidad reducida al ET-1 exógeno.
- Estas anomalías de la vía ET-1 pueden contribuir a las complicaciones vasculares diabéticas.
Videos de Conceptos Relacionados
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:22Diabetes Insipidus II: Pathophysiology
Normally, water balance is maintained through three interconnected mechanisms: the hypothalamic thirst center, the synthesis and release of antidiuretic hormone (ADH, or vasopressin), and the kidneys' responsiveness to this hormone. ADH is synthesized in the hypothalamus, released from the posterior pituitary, and acts on the distal nephron, allowing water reabsorption and concentrated urine production.Diabetes Insipidus and Its TypesIn diabetes insipidus (DI), this regulatory system is...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.